Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison

Cameron, Chris; Zummo, Jacqueline; Desai, Dharmik N.; Drake, Christine; Hutton, Brian; Kotb, Ahmed; Weiden, Peter J.

doi:10.1016/j.jval.2017.03.010

Cited by 6 publications

(5 citation statements)

References 22 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second most relevant result of this work is that we did not identify significant differences in tolerability and effectiveness profiles between the Ari-LAI and the PP1M/PP3M groups. While, on the one hand, this could be explained by the reduced sample size, it should, however, be considered that this data remains in continuity with both what was assessed in our previous study [ 16 ] and similar researches [ 34 , 35 ]. Indeed, a retrospective study in a real-world clinical setting comparing the effectiveness of 1 year treatment with Ari-LAI, haloperidol LAI and PP1M in a sample of patients with SCZ identified similar tolerability and effectiveness profiles [ 36 ].…”

Section: Discussionsupporting

confidence: 84%

Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study

et al. 2023

View full text Add to dashboard Cite

We hypothesized that shifting from oral second-generation antipsychotics (SGA) to their long-acting injectable (LAI) counterpart would be beneficial for the psychopathological, cognitive, social, and general health domains in outpatients suffering from schizophrenia. We aimed to evaluate the prospective usefulness of SGA-LAI treatment by carrying out a head-to-head comparison of two different medications (i.e., aripiprazole monohydrate (Ari-LAI) and paliperidone palmitate 1 and 3 month (PP1M, PP3M)) in a real-world setting, assessing the effectiveness and tolerability of Ari-LAI and PP1M/PP3M over a 15 month follow-up. A total of 69 consecutive individuals affected by schizophrenia were screened for eligibility. Finally, 46 outpatients (29 treated with Ari-LAI, 13 with PP1M, and four with PP3M) were evaluated through clinical, functional, and neuropsychological assessment administrated at baseline and after 3-, 12-, and 15-month follow-up periods. Moreover, periodic general medical evaluations were carried out. We estimated an overall improvement over time on the explored outcomes, without differences with respect to the type of LAI investigated, and with a global 16.4% dropout rate. Our findings suggest that switching from oral SGA to SGA-LAIs represents a valid and effective treatment strategy, with significant improvements on psychopathological, cognitive, social, and clinical variables for patients suffering from schizophrenia, regardless of the type of molecule chosen.

show abstract

Section: Discussionsupporting

confidence: 84%

Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The extent of these reductions was similar, with the range of mean differences spanning from −8.12 to −12.01, with overlapping 95% credible intervals. These results, in addition to a similar incidence of TEAEs for both AL and PP, supported the finding that AL and PP were equally efficacious [ 98 ].…”

Section: Clinical Studies: Safety and Efficacysupporting

confidence: 83%

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review

Maini

Gould

Hicks

et al. 2021

Neurology International

View full text Add to dashboard Cite

Purpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health disorder that currently affects approximately 3.3 million people in the United States. Its symptoms, which must be present for more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Aripiprazole lauroxil is a long-acting intramuscular injection that works as a combination of partial agonist activity at D2 and 5-HT1A receptors combined with antagonist activity at 5-HT2A receptors. It can be dosed as a 4-, 6-, or 8-week injection, depending on oral dosage. Aripiprazole lauroxil was FDA approved in October of 2015. Summary. Schizophrenia is a severe psychiatric disorder if left untreated. There are multiple medications to help treat schizophrenia. One antipsychotic agent, aripiprazole lauroxil, offers long duration injections that optimize and improve compliance. Known side effects include weight gain, akathisia, neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension. Aripiprazole lauroxil is an FDA-approved drug that can be administered monthly, every six weeks, or every two months and has been shown to be both safe and effective.

show abstract

“…12,13 Although a newer study reported that psychotropic medication non-adherence was high, and was influenced by various factors (such as patients' individual behavior, social or family support, clinical or illness and treatment-related, and overall health care systemrelated factors) operating at different levels, 14 LAI formulations of paliperidone palmitate 3-monthly (PP3M), aripiprazole, olanzapine, and paliperidone palmitate once-monthly (PP1M) showed the highest effect sizes and certainty of evidence for both relapse prevention and acceptability in the maintenance treatment of adults with nonaffective psychoses. 15 Thus, LAI antipsychotics (LAIAs) may promote the development in the later stages of schizophrenia, and introducing the patient to a long-acting formulation for ongoing maintenance therapy while treating acute psychotic episodes, [16][17][18][19] or nonaffective psychoses 15 may assist clinicians in establishing optimal treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety

Zhao¹,

Qin²,

Mao³

et al. 2023

NDT

View full text Add to dashboard Cite

Purpose The aim of this study was to assess the efficacy and safety of paliperidone palmitate (PP) treatment compared with risperidone long-acting injectable (LAI) treatments for patients with schizophrenia. Patients and Methods Data mining was conducted in April 2022 across PubMed, Web of Science, Embase, the Cochrane Library, ClinicalTrials.gov, and PsycINFO. All published randomized controlled trials (RCTs) that assessed the effect of PP treatment for patients with schizophrenia when compared with the risperidone-LAIAs group were included. Relevant data were extracted and synthesized narratively. Results were expressed as standardized mean differences (SMDs) or risk ratios (RRs), with 95% confidence intervals (CIs). Results Four RCTs with 2451 patients met all the inclusion and exclusion criteria. Efficacy analyses showed no significant statistical differences in Positive and Negative Syndrome Scale (PANSS) total score changes at the endpoint (SMD = 0.10, P = 0.19), or in response rates (RR = 0.93; P = 0.40). Regarding the safety outcomes, PP treatment showed significantly increased risks of discontinuation rates for any reason (35.7% vs 30.4%; RR = 1.19; 95% CI, 1.03 to 1.39; P = 0.02) and nonsignificantly increased risks of total treatment emergent adverse events (TEAEs) (66.6% vs.64.8%; RR = 1.01; 95% CI, 0.94 to 1.09; P = 0.78) compared with the risperidone-LAIAs-treated group. Furthermore, PP may significantly increase total discontinuation rates compared with risperidone-LAIAs. Conclusion Our meta-analysis did not find a more beneficial effect of PP compared to risperidone-LAIAs treatments for schizophrenia. Clinicians should interpret and translate our data with caution, as the meta-analysis was based on a limited number of randomized controlled trials and patients.

show abstract

Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison

Abstract: These results suggest that both AL and PP are effective for treatment of adults experiencing acute exacerbation of schizophrenia.

Cited by 6 publications

References 22 publications

Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study

Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety

Contact Info

Product

Resources

About